HC Wainwright reiterated their buy rating on shares of Femasys (NASDAQ:FEMY – Free Report) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock. Femasys Price Performance NASDAQ:FEMY opened at $0.43 on Thursday. The firm has a market cap of $6.48 million, a P/E ratio […]
Femasys (FEMY) Buy Rating Reaffirmed at Chardan Capital modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® - Three product approvals achieved. -Today at 08:02 am- MarketScreener
- Raised $3.9 million in a registered direct offering ATLANTA, August 10, 2023 Femasys Inc. , a biomedical company focused on meeting women s unmet needs. -Today at 08:08 am- MarketScreener
Femasys Inc. (NASDAQ:FEMY – Get Free Report) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 2,640,000 shares, an increase of 65,900.0% from the July 15th total of 4,000 shares. Approximately 21.0% of the shares of the stock are short sold. Based on an average daily […]